Ramaswamy's Axovant Alzheimer drug fails, stock crashes 75% after pump-and-dump

Vivek Ramaswamy’s Axovant Sciences announced its Alzheimer’s drug intepirdine failed clinical trials, causing the stock to crash 75% in one day from $200 to eventually 40 cents. Ramaswamy had sold $40 million of his personal stake at the peak while hyping the drug in media. The drug had …